Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yasuharu Nakashima, Masakazu Kondo, Eisuke Shono, Takashi Ishinishi, Hiroshi Tsukamoto, Koji Kuroda, Akira Maeyama, Hiroshi Harada, Masayuki Maekawa, Takashi Shimauchi, Ryuji Nagamine, Hiroshi Jojima, Seiji Yoshizawa, Tomomi Tsuru, Takeshi Otsuka, Hisaaki Miyahara, Eiichi Suematsu, Ken Wada, Shigeru Yoshizawa, Yasushi Inoue, Takaaki Fukuda, Satoshi Ikemura & Akihisa Haraguchi. (2020) Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice. Modern Rheumatology 30:5, pages 807-815.
Read now
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Keiji Maeda. (2019) Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opinion on Drug Delivery 16:6, pages 639-648.
Read now
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Kazuyuki Yoshizaki. (2019) IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology 29:2, pages 258-267.
Read now
Read now
Articles from other publishers (10)
Shuhei Yoshida, Eiji Suzuki, Haruki Matsumoto, Kohei Yokose, Yuya Fujita, Jumpei Temmoku, Naoki Matsuoka, Makiko Yashiro-Furuya, Tomoyuki Asano, Shuzo Sato, Hiroshi Watanabe & Kiyoshi Migita. (2023) Effectiveness of combination tocilizumab and glucocorticoids as an induction therapy in patients with Takayasu arteritis: An observational study. Modern Rheumatology 33:2, pages 360-366.
Crossref
Crossref
Ayten Yazici, Özlem Özdemir Işık, Ediz Dalkılıç, Süleyman Serdar Koca, Yavuz Pehlivan, Soner Şenel, Nevsun Inanc, Servet Akar, Sema Yılmaz, Özgül Soysal Gündüz, Ayse Cefle, Ömer Fatih Karakaş & Fatos Onen. (2022) A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry. Scientific Reports 12:1.
Crossref
Crossref
Simon Kuster, Suzana Jordan, Muriel Elhai, Ulrike Held, Klaus Steigmiller, Cosimo Bruni, Fabio Cacciapaglia, Serena Vettori, Elise Siegert, Simona Rednic, Veronica Codullo, Paolo Airo, Yolanda Braun-Moscovici, Nicolas Hunzelmann, Maria Joao Salvador, Valeria Riccieri, Ana-Maria Gheorghiu, Juan José Alegre Sancho, Katarzyna Romanowska-Prochnicka, Ivan Castellví, Ina Kötter, Marie-Elise Truchetet, FJ López-Longo, Pavel I Novikov, Alessandro Giollo, Yuichiro Shirai, Laura Belloli, Elisabetta Zanatta, Eric Hachulla, Vanessa Smith, Chris Denton, Ruxandra M Ionescu, Tim Schmeiser, Joerg H W Distler, Armando Gabrielli, Anna-Maria Hoffmann-Vold, Masataka Kuwana, Yannick Allanore & Oliver Distler. (2022) Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open 8:2, pages e002477.
Crossref
Crossref
György Nagy, Pál Géher, László Tamási, Edit Drescher, Péter Keszthelyi, Judit Pulai, László Czirják, Zoltán Szekanecz, Gergely Kiss & László Kovács. (2022) Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study. Rheumatology Advances in Practice 6:2.
Crossref
Crossref
ShanleeM Stevens, Nathan Pirakitikulr & BradfordW Lee. (2022) Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers. Taiwan Journal of Ophthalmology 12:1, pages 39.
Crossref
Crossref
Yoshikazu Nakaoka, Mitsuaki Isobe, Yoshiya Tanaka, Tomonori Ishii, Seido Ooka, Hiroaki Niiro, Naoto Tamura, Shogo Banno, Hajime Yoshifuji, Yasushi Sakata, Atsushi Kawakami, Tatsuya Atsumi, Shunsuke Furuta, Hitoshi Kohsaka, Katsuya Suzuki, Ryoki Hara, Yasuhiro Maejima, Hiroshi Tsukamoto, Yoshinari Takasaki, Katsuhisa Yamashita, Norihiro Okada, Shinji Yamakido, Syuji Takei, Shumpei Yokota & Norihiro Nishimoto. (2020) Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology 59:9, pages 2427-2434.
Crossref
Crossref
Ennio G. Favalli. (2020) Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatology and Therapy 7:3, pages 473-516.
Crossref
Crossref
Sandra Rodríguez, Andrés Muñoz, Rosa-Helena Bustos & Diego Jaimes. (2020) Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. Biomedicines 8:9, pages 303.
Crossref
Crossref
Jean Darloy, Nicolas Segaud, Jean-Hugues Salmon, Jean-Paul Eschard, Vincent Goëb, Xavier Deprez, Marie-Hélène Guyot, Eric Houvenagel, Nicolas Lecuyer, Laurent Marguerie, Samuel Gally, David Pau, Isabelle Idier, Guy Baudens & René-Marc Flipo. (2019) Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study. Rheumatology and Therapy 6:1, pages 61-75.
Crossref
Crossref
. (2018) Tocilizumab. Reactions Weekly 1724:1, pages 346-346.
Crossref
Crossref